Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.70 |
| ▸ | CNR2 | P34972 | 5/20 | 0.70 |
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915904 | 0.98 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL1916424 | 0.98 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL11222635 | 0.98 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL3372474 | 0.93 | CNR1 (0.70) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL17556035 | 0.92 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL4886505 | 0.92 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL4886501 | 0.92 | CNR1 (0.68) | CNR1CNR2FAAHFASNKDM4E | |
| SCHEMBL7638596 | 0.90 | CNR1 (0.67) | CNR1CNR2FAAH | |
| SCHEMBL17091577 | 0.90 | CNR1 (0.67) | CNR1CNR2FAAH | |
| SCHEMBL5884581 | 0.89 | CNR1 (0.65) | CNR1CNR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | TRPV1, TRPA1, P2RX3 | CNR1 195/4885CNR2 99/4885FAAH 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.